MedPath

Technoderma Medicines, Inc.

Technoderma Medicines, Inc. logo
πŸ‡¨πŸ‡³China
Ownership
Holding
Established
2014-03-31
Employees
-
Market Cap
-
Website
http://www.tkskin.com

Clinical Trials

5

Active:0
Completed:5

Trial Phases

2 Phases

Phase 1:3
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 2
2 (40.0%)

Study of TDM-180935 in Atopic Dermatitis Patients

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: TDM-180935 topical ointment 1.0%
Drug: TDM-180935 topical ointment 2.0%
Drug: TDM-180935 topical vehicle ointment 1
Drug: TDM-180935 topical vehicle ointment 2
First Posted Date
2024-04-12
Last Posted Date
2025-04-24
Lead Sponsor
Technoderma Medicines Inc.
Target Recruit Count
24
Registration Number
NCT06363461
Locations
πŸ‡ΊπŸ‡Έ

Site 5, Rolling Meadows, Illinois, United States

πŸ‡ΊπŸ‡Έ

Site 8, Covington, Louisiana, United States

πŸ‡ΊπŸ‡Έ

Site 4, New Brighton, Minnesota, United States

and more 4 locations

Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia

Phase 2
Completed
Conditions
Alopecia, Androgenetic
Interventions
Drug: TDM-105795, 0.0025%
Drug: TDM-105795, 0.02%
Drug: TDM-105795 topical vehicle solution
First Posted Date
2023-04-06
Last Posted Date
2024-11-27
Lead Sponsor
Technoderma Medicines Inc.
Target Recruit Count
71
Registration Number
NCT05802173
Locations
πŸ‡ΊπŸ‡Έ

Site 12, North Little Rock, Arkansas, United States

πŸ‡ΊπŸ‡Έ

Site 4, Rolling Meadows, Illinois, United States

πŸ‡ΊπŸ‡Έ

Site 7, Plainfield, Indiana, United States

and more 10 locations

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2022-09-01
Last Posted Date
2023-11-18
Lead Sponsor
Technoderma Medicines Inc.
Target Recruit Count
58
Registration Number
NCT05525468
Locations
πŸ‡ΊπŸ‡Έ

TKL Research, Inc., Fair Lawn, New Jersey, United States

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Phase 1
Completed
Conditions
Alopecia, Androgenetic
Interventions
Drug: Placebo
First Posted Date
2022-02-17
Last Posted Date
2023-03-14
Lead Sponsor
Technoderma Medicines Inc.
Target Recruit Count
32
Registration Number
NCT05244980
Locations
πŸ‡ΊπŸ‡Έ

TCR Medical Corporation, San Diego, California, United States

πŸ‡ΊπŸ‡Έ

J&S Studies, Inc., College Station, Texas, United States

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

Phase 1
Completed
Conditions
Alopecia, Androgenetic
Interventions
Drug: Placebo
First Posted Date
2021-06-04
Last Posted Date
2022-04-27
Lead Sponsor
Technoderma Medicines Inc.
Target Recruit Count
30
Registration Number
NCT04913519
Locations
πŸ‡ΊπŸ‡Έ

TCR Medical Corporation, San Diego, California, United States

πŸ‡ΊπŸ‡Έ

J&S Studies, Inc., College Station, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.